Epidermal growth factor receptor mutations: gefitinib and erlotinib treatment of non-small cell lung cancer research targets
Gefitinib and erlotinib are epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) class of drugs, is currently the treatment of non-small cell lung cancer (NSCLC) hot spots, has been confirmed in several clinical trials, East Asians, women, no history of smoking and effective in patients with adenocarcinoma, further research reveals cancer patients with EGFR tyrosine kinase domain mutations on EGFR-TKI sensitivity are closely related. These mutations include frame deletions, point mutations and other types. This article reviews the EGFR mutation status and progress.
Epidermal growth factor receptor mutations: gefitinib and erlotinib treatment of non-small cell lung cancer research targets
ReplyDeleteGefitinib and erlotinib are epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) class of drugs, is currently the treatment of non-small cell lung cancer (NSCLC) hot spots, has been confirmed in several clinical trials, East Asians, women, no history of smoking and effective in patients with adenocarcinoma, further research reveals cancer patients with EGFR tyrosine kinase domain mutations on EGFR-TKI sensitivity are closely related. These mutations include frame deletions, point mutations and other types. This article reviews the EGFR mutation status and progress.
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
HIV-1 integrase inhibitor
BMS-707035
Nelfinavir
Tezampanel
NS309
Vernakalant
Vernakalant Hydrochloride
Dronedarone hydrochloride
Dronedarone
Ruxolitinib